CereVasc is a medical device company focused on the development of novel, minimally invasive treatments for patients with neurological diseases.
CereVasc's ultimate goal is to transform the common procedure into an outpatient, one-day surgery alternative.
CereVasc was co-founded in 2014 by Dan Levangie, Patrick Sulivan, Carl Heilman and Adel Malek. The company is headquartered in Boston, Massachusetts.
CereVasc's first product, the eShunt System, is the first minimally invasive cerebrospinal fluid shunt designed to avoid the need for invasive surgery and extended hospitalization associated with the current surgical treatment of hydrocephalus using ventriculo-peritoneal shunts.
The eShunt System has the potential to significantly improve patient outcomes and substantially decrease the overall cost of surgical treatment of this life-threatening condition.
CereVasc has closed its expanded Series A round with $43.9M. The investment was led by the Perceptive Xontogeny Venture (PXV) Fund and ATON Partners, LLC.